Claudia Rodriguez

Claudia Rodriguez

Auto-generated profile, based on publicly available information

Claudia Rodriguez

Department of Population and Public Health Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, California

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2024 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
AAAngel Arizpe
Angel Arizpe
TCTiffany M. Chapman
Tiffany M. Chapman
CRClaudia Rodriguez
Claudia Rodriguez
ACAlberto Carvajal
Alberto Carvajal
KQKatelyn J. Queen
Katelyn J. Queen
AFAlbert Farias
Albert Farias
Background: Cancer survivors are at increased risk for cardiometabolic comorbidities following cancer treatment, which may be further exacerbated by cannabis and alcohol use. We aimed to examine the direct relationships of cannabis, alcohol, and the co-use of both substances with cardiometabolic risk factors and to explore disparities by race/ethnicity and sex. Methods: Cross-sectional data were extracted from adult cancer survivors in the “All of Us” from 2018 to 2022. Cannabis use was defined as occasional or frequent/regular cannabis use (vs. never) in the past 3 months and hazardous alcohol intake (AUDIT-C >3 for females; AUDIT-C >4 for males) versus nonhazardous in the past year, respectively. Co-use was defined as participants who engaged in regular cannabis and hazardous alcohol intake. We identified binary cardiovascular, immune, and metabolic system biomarkers, with high values defined by clinically established cutoffs or >75th percentile. We used multivariable logistic regression adjusting for sociodemographic and clinical factors. Results: In our sample (N = 7,054), 7.6% were Hispanic, 6.2% were Black, and 86.2% were White cancer survivors. Less than 5% of Hispanic and White survivors reported substance co-use compared with 7% of Black survivors. Compared with never-users, co-users were 1.58 (95% confidence interval, 1.14–2.19) more likely to have high blood pressure. No significant associations were found between co-use and immune biomarkers or sex differences. Conclusions: Co-use of cannabis and hazardous alcohol may worsen high blood pressure in survivors, who are at higher risk for cardiometabolic comorbidities. Impact: The study investigates substance use and cardiometabolic biomarkers, urging much research on their effects on cancer survivors.

9 January 2025
Verified
Other
Open access
PDF file
AAAngel Arizpe
Angel Arizpe
TCTiffany M. Chapman
Tiffany M. Chapman
CRClaudia Rodriguez
Claudia Rodriguez
ACAlberto Carvajal
Alberto Carvajal
KQKatelyn J. Queen
Katelyn J. Queen
AFAlbert Farias
Albert Farias
Supplementary Table 1: Shows the distribution of cancer survivors excluded compared to those included in our final sample by all study variables

9 January 2025
Verified
Other
Open access
PDF file
AAAngel Arizpe
Angel Arizpe
TCTiffany M. Chapman
Tiffany M. Chapman
CRClaudia Rodriguez
Claudia Rodriguez
ACAlberto Carvajal
Alberto Carvajal
KQKatelyn J. Queen
Katelyn J. Queen
AFAlbert Farias
Albert Farias
Supplementary Table 2: Exploration of missing outcome data by exposure variables

9 January 2025
Verified
Other
Open access
AAAngel Arizpe
Angel Arizpe
TCTiffany M. Chapman
Tiffany M. Chapman
CRClaudia Rodriguez
Claudia Rodriguez
ACAlberto Carvajal
Alberto Carvajal
KQKatelyn J. Queen
Katelyn J. Queen
AFAlbert Farias
Albert Farias
Background:Cancer survivors are at increased risk for cardiometabolic comorbidities following cancer treatment, which may be further exacerbated by cannabis and alcohol use. We aimed to examine the direct relationships of cannabis, alcohol, and the co-use of both substances with cardiometabolic risk factors and to explore disparities by race/ethnicity and sex.Methods:Cross-sectional data were extracted from adult cancer survivors in the “All of Us” from 2018 to 2022. Cannabis use was defined as occasional or frequent/regular cannabis use (vs. never) in the past 3 months and hazardous alcohol intake (AUDIT-C >3 for females; AUDIT-C >4 for males) versus nonhazardous in the past year, respectively. Co-use was defined as participants who engaged in regular cannabis and hazardous alcohol intake. We identified binary cardiovascular, immune, and metabolic system biomarkers, with high values defined by clinically established cutoffs or >75th percentile. We used multivariable logistic regression adjusting for sociodemographic and clinical factors.Results:In our sample (N = 7,054), 7.6% were Hispanic, 6.2% were Black, and 86.2% were White cancer survivors. Less than 5% of Hispanic and White survivors reported substance co-use compared with 7% of Black survivors. Compared with never-users, co-users were 1.58 (95% confidence interval, 1.14–2.19) more likely to have high blood pressure. No significant associations were found between co-use and immune biomarkers or sex differences.Conclusions:Co-use of cannabis and hazardous alcohol may worsen high blood pressure in survivors, who are at higher risk for cardiometabolic comorbidities.Impact:The study investigates substance use and cardiometabolic biomarkers, urging much research on their effects on cancer survivors.